Pre-meeting survey
Please complete the following survey to help support the discussion at the upcoming meeting. Note that there will be the opportunity to expand on your responses during the meeting discussion.
Q3. How beneficial is it to conduct biomarker testing, such as the protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein-L3 tests, for the following groups of patients for HCC surveillance? *
1 (Not beneficial)2345 (Highly beneficial)
1 (Not beneficial)
2
3
4
5 (Highly beneficial)
1 (Not beneficial)2345 (Highly beneficial)
1 (Not beneficial)
2
3
4
5 (Highly beneficial)
1 (Not beneficial)2345 (Highly beneficial)
1 (Not beneficial)
2
3
4
5 (Highly beneficial)
1 (Not beneficial)2345 (Highly beneficial)
1 (Not beneficial)
2
3
4
5 (Highly beneficial)
Q4. The value of the PIVKA-II test in HCC surveillance is to: *
1 (Not useful)2345 (Very useful)
1 (Not useful)
2
3
4
5 (Very useful)
1 (Not useful)2345 (Very useful)
1 (Not useful)
2
3
4
5 (Very useful)
1 (Not useful)2345 (Very useful)
1 (Not useful)
2
3
4
5 (Very useful)
1 (Not useful)2345 (Very useful)
1 (Not useful)
2
3
4
5 (Very useful)